Neoadjuvant Anti-PD-1 Antibody SHR-1210 and Radiation in Resectable Esophageal Squamous Cell Carcinoma
Status:
Unknown status
Trial end date:
2020-07-01
Target enrollment:
Participant gender:
Summary
The objective of this study is to evaluate the efficacy and safety of radiation therapy
combined with anti-PD-1 antibody SHR-1210 followed by surgery in treating patients with
resectable esophageal squamous cell carcinoma